Trepipam
![]() | |
| Clinical data | |
|---|---|
| Other names | SCH-12679; SCH12679 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C19H23NO2 |
| Molar mass | 297.398 g·mol−1 |
| 3D model (JSmol) | |
| Specific rotation | +31.8° |
| Density | 1.072 ± 0.06 g/cm3 (predicted) |
| Melting point | 105–106 °C (221–223 °F) (experimental) |
| Boiling point | 416.8 ± 45.0 °C (782.2 ± 81.0 °F) (predicted) |
| |
| |
Trepipam (INN; developmental code name SCH-12679) is a dopamine receptor agonist of the benzazepine group that was never marketed.[1] It acts specifically as an agonist of the dopamine D1 receptor.[2] It is closed related structurally to fenoldopam, a peripherally acting selective D1 receptor partial agonist which is used as an antihypertensive agent.
References
- ^ Lednicer D (4 March 2009). Strategies for Organic Drug Synthesis and Design. John Wiley & Sons. pp. 495–. ISBN 978-0-470-39959-0.
- ^ Goode-Romero G, Winnberg U, Domínguez L, Ibarra IA, Vargas R, Winnberg E, Martínez A (December 2020). "New information of dopaminergic agents based on quantum chemistry calculations". Sci Rep. 10 (1): 21581. Bibcode:2020NatSR..1021581G. doi:10.1038/s41598-020-78446-4. PMC 7725812. PMID 33299000.
